Sunshine Lake Pharma (HKG:6887) expects to report a loss attributable to equity shareholders of about 590 million yuan for the six months ended June 30, widening from a loss of about 50 million yuan a year earlier, according to a Hong Kong bourse filing.
The pharmaceutical firm attributed the wider loss to lower sales of Kewei, the company's core influenza treatment, as the influenza outbreak eased in the first half of 2026, according to a Monday Hong Kong bourse filing.
The company expects to publish its interim results on Aug. 31.